Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Up 60.9% in December

Palvella Therapeutics, Inc. (NASDAQ:PVLA) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 1,326,830 shares, a growth of 60.9% from the December 15th total of 824,522 shares. Based on an average daily volume of 327,392 shares, the short-interest ratio is currently 4.1 days. Approximately 14.1% of the company’s shares are short sold. Approximately 14.1% of the company’s shares are short sold. Based on an average daily volume of 327,392 shares, the short-interest ratio is currently 4.1 days.

Palvella Therapeutics Trading Down 1.3%

Shares of PVLA stock opened at $103.98 on Friday. Palvella Therapeutics has a 12 month low of $12.10 and a 12 month high of $114.69. The stock has a 50 day moving average of $95.63 and a two-hundred day moving average of $67.42. The company has a market capitalization of $1.23 billion, a P/E ratio of -39.54 and a beta of -0.16.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). Sell-side analysts predict that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $96.47, for a total transaction of $415,013.94. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

Hedge funds have recently modified their holdings of the stock. Millennium Management LLC acquired a new position in Palvella Therapeutics during the first quarter worth $7,553,000. Goldman Sachs Group Inc. bought a new stake in shares of Palvella Therapeutics in the 1st quarter worth about $533,000. Clio Asset Management LLC acquired a new stake in shares of Palvella Therapeutics during the 2nd quarter worth about $2,063,000. Geode Capital Management LLC lifted its holdings in Palvella Therapeutics by 84.7% during the 2nd quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock valued at $3,923,000 after purchasing an additional 79,787 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in Palvella Therapeutics in the second quarter valued at about $37,000. 40.11% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PVLA has been the topic of a number of research reports. Stifel Nicolaus increased their price objective on Palvella Therapeutics from $87.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, November 24th. HC Wainwright set a $200.00 price objective on shares of Palvella Therapeutics and gave the company a “buy” rating in a research note on Monday, December 15th. TD Cowen increased their target price on shares of Palvella Therapeutics from $97.00 to $133.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Craig Hallum assumed coverage on Palvella Therapeutics in a research report on Thursday, December 4th. They issued a “buy” rating and a $175.00 price target for the company. Finally, Chardan Capital increased their price objective on Palvella Therapeutics from $110.00 to $174.00 and gave the company a “buy” rating in a report on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $158.69.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.